A preclinical study in China showed that the higher infiltration of cancer-associated fibroblasts was related to innate resistance of AM to PD-1 inhibitors, and the FAK inhibitor defactinib enhanced the efficacy of anti-PD-1 antibodies. Here, PTK2 is linked to cancer.